Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials

特里普坦 里扎曲普坦 医学 偏头痛 耐受性 苏马曲普坦 临床试验 不利影响 麻醉 安慰剂 内科学 兴奋剂 替代医学 病理 受体
作者
Michel Dominique Ferrari,Krista I Roon,Richard B. Lipton,Peter James Goadsby
出处
期刊:The Lancet [Elsevier BV]
卷期号:358 (9294): 1668-1675 被引量:1050
标识
DOI:10.1016/s0140-6736(01)06711-3
摘要

The triptans, selective serotonin 5-HT(1B/1D) agonists, are very effective acute migraine drugs with a well- developed scientific rationale. Seven different triptans will soon be clinically available, making evidence-based selection guidelines necessary. Triptan trials have similar designs, facilitating meta-analysis; this will provide a foundation for using triptans in clinical practice.We asked pharmaceutical companies and the principal investigators of company-independent trials for raw patient data of all double-blind, randomised, controlled, clinical trials of oral triptans in migraine. We calculated summary estimates across studies for important efficacy and tolerability parameters, and separately summarised direct comparator trials.53 clinical trials (12 unpublished) involving 24089 patients, met the criteria for inclusion. Mean results for 100 mg sumatriptan were 59% (95% CI 57-60) for 2 h headache response (improvement from moderate or severe to mild or no pain); 29% (27-30) for 2 h pain free (improvement to no pain); 20% (18-21) for sustained pain free (pain free by 2 h and no headache recurrence or use of rescue medication 2-24 h post dose); and 67% (63-70) for consistency (response in at least two of three treated attacks); placebo-subtracted proportions for patients with at least one adverse event (AE) were 13% (8-18), for at least one central nervous system AE 6% (3-9), and for at least one chest AE 1.9% (1.0-2.7). Compared with these data, 10 mg rizatriptan showed better efficacy and consistency, and similar tolerability; 80 mg eletriptan showed better efficacy, similar consistency, but lower tolerability; 12.5 mg almotriptan showed similar efficacy at 2 h but better other results; 2.5 mg naratriptan and 20 mg eletriptan showed lower efficacy and (the first two) better tolerability; 2.5 mg and 5 mg zolmitriptan, 40 mg eletriptan, and 5 mg rizatriptan showed very similar results. The results of the 22 trials that directly compared triptans show the same overall pattern. We received no data on frovatriptan, but publicly available data suggest lower efficacy.At marketed doses, all oral triptans were effective and well tolerated. 10 mg rizatriptan, 80 mg eletriptan, and 12.5 mg almotriptan provide the highest likelihood of consistent success.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李李李完成签到,获得积分10
刚刚
1秒前
1秒前
领导范儿的应助被时平谊采纳,获得10
2秒前
小秀发布了新的文献求助10
2秒前
万能图书馆的应助被冷酷叫兽采纳,获得10
3秒前
min完成签到,获得积分10
5秒前
追寻一一完成签到 ,获得积分10
5秒前
6秒前
6秒前
6秒前
6秒前
Li发布了新的文献求助10
7秒前
8秒前
9秒前
Ming发布了新的文献求助10
10秒前
DZS完成签到 ,获得积分10
10秒前
10秒前
积极凌兰完成签到 ,获得积分10
10秒前
郭娅楠发布了新的文献求助10
11秒前
orixero的应助被包包糖在摸鱼采纳,获得10
12秒前
leilei发布了新的文献求助10
13秒前
Zllu完成签到,获得积分10
14秒前
Lucas的应助被科研通管家采纳,获得10
14秒前
情怀的应助被科研通管家采纳,获得10
14秒前
初景的应助被科研通管家采纳,获得20
14秒前
Orange的应助被科研通管家采纳,获得10
14秒前
14秒前
wanci的应助被jls采纳,获得10
14秒前
华仔的应助被科研通管家采纳,获得30
14秒前
天天快乐的应助被科研通管家采纳,获得10
15秒前
彭于晏的应助被科研通管家采纳,获得10
15秒前
Hello的应助被科研通管家采纳,获得10
15秒前
berg发布了新的文献求助10
15秒前
FashionBoy的应助被王肄博采纳,获得10
15秒前
15秒前
shiyin完成签到 ,获得积分10
16秒前
17秒前
乐观的凝梦完成签到,获得积分10
18秒前
黄紫红完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186676
求助须知:如何正确求助?哪些是违规求助? 9574945
关于积分的说明 21839037
捐赠科研通 7784275
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559187
邀请新用户注册赠送积分活动 2481611